Semaglutide vs SLU-PP-332
Side-by-side comparison of Semaglutide and SLU-PP-332: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Semaglutide
SLU-PP-332
Semaglutide
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural…
Lowest listed price: $39.00 across 12 listings
Full Semaglutide profileSLU-PP-332
SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023…
Lowest listed price: $69.99 across 5 listings
Full SLU-PP-332 profileSide-by-side comparison
| Attribute | Semaglutide | SLU-PP-332 |
|---|---|---|
| Category | Metabolic & Weight Loss | Performance |
| Research Stage | FDA Approved | Preclinical |
| Mechanism of Action | GLP-1 Receptor Agonism and cAMP Signaling Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and other tissues. Upon binding,… | SLU-PP-332 acts through pan-agonism of the three estrogen-related receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3), a subfamily of orphan nuclear receptors that regulate oxidative metabolism, mitochondrial biogenesis, and exercise-responsive gene expression. The… |
| Half-Life | ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification | — |
| Typical Dose Range | Diabetes (Ozempic): 250-1000 mcg weekly; Weight management (Wegovy): 2400 mcg weekly (after 16-week titration); Oral (Rybelsus): 3-14 mg daily | Research compound — no established human doses. Animal studies: 10-50 mg/kg |
| Dosing Frequency | Once weekly subcutaneous injection | — |
| Administration | Subcutaneous (weekly), Oral (daily) | — |
| Side Effects | Nausea (especially at initiation — dose-dependent), vomiting, diarrhea, constipation, abdominal pain, decreased appetite (therapeutic effect), headache, fatigue, dizziness. Rare: pancreatitis, gallbladder issues, thyroid C-cell tumors (rodent studies).… | The side effect profile of SLU-PP-332 in humans is undocumented because no clinical trials have been conducted. Rodent studies report generally acceptable tolerability at doses producing exercise-mimetic metabolic effects, without overt signs of toxicity on… |
| Molecular Weight | 4113.6 Da | 290.3 g/mol |
| Common Vial Sizes | 3mg, 5mg, 10mg | — |
Price History
4 data points- OF
- Half Nattys
- Ion Peptide
- Disguised Alpha
Price History
3 data points- Half Nattys
- Ion Peptide
- BHG Labs
Semaglutide: potential benefits
- Mean body weight reduction of 14.9% at 68 weeks in STEP 1 trial (PMID: 33567185)
- Sustained weight loss of ~15% (-15.2%) maintained through 104 weeks in STEP 5 trial (PMID: 36216945)
- 20% relative reduction in major adverse cardiovascular events (HR 0.80) in the SELECT trial (PMID: 37952131)
- HbA1c reduction of 1.5-1.8% in type 2 diabetes (SUSTAIN program)
- Reduction in systemic inflammation (lower hs-CRP) observed in SELECT
- Available in both subcutaneous (weekly) and oral (daily) formulations
- Improved cardiometabolic risk factors including blood pressure and lipid profile
SLU-PP-332: potential benefits
- Exercise mimicry without physical exertion
- Enhanced fat oxidation
- Increased mitochondrial biogenesis
- Improved endurance capacity
- Muscle fiber type conversion
- Metabolic health improvement
Frequently asked
What's the difference between Semaglutide and SLU-PP-332?
Semaglutide is a metabolic & weight loss that glp-1 receptor agonism and camp signaling semaglutide binds to the glp-1 receptor (glp-1r), a class b g-protein coupled receptor expressed on pancreatic beta cells, hypothalamic…. SLU-PP-332 is a performance that slu-pp-332 acts through pan-agonism of the three estrogen-related receptors (errα/nr3b1, errβ/nr3b2, errγ/nr3b3), a subfamily of orphan nuclear receptors that regulate oxidative…. The two differ in mechanism, half-life (~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification vs not reported), and typical dose range.
Which has the longer half-life, Semaglutide or SLU-PP-332?
Semaglutide has a half-life of ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification. SLU-PP-332 has a half-life of not reported. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Semaglutide or SLU-PP-332?
Lowest listed price on BodyHackGuide: Semaglutide from $39.00, SLU-PP-332 from $69.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Semaglutide and SLU-PP-332?
Stacking depends on mechanism overlap, safety profile, and goals. Semaglutide and SLU-PP-332 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Semaglutide or SLU-PP-332
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.